Non-drug efflux function of ABCC5 promotes enzalutamide resistance in castration-resistant prostate cancer via upregulation of P65/AR-V7

[1]  Xuesong Li,et al.  Upregulation of ATP Binding Cassette Subfamily C Member 5 facilitates Prostate Cancer progression and Enzalutamide resistance via the CDK1-mediated AR Ser81 Phosphorylation Pathway , 2021, International journal of biological sciences.

[2]  Shouhong Gao,et al.  Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer , 2021, Cancer cell international.

[3]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[4]  P. Nelson,et al.  Role of androgen receptor splice variant 7 (AR-V7) in prostate cancer resistance to 2nd generation androgen receptor signaling inhibitors , 2020, Oncogene.

[5]  H. Klocker,et al.  Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer , 2020, Cancers.

[6]  B. Dai,et al.  Targeting CPT1B as a potential therapeutic strategy in castration‐resistant and enzalutamide‐resistant prostate cancer , 2020, The Prostate.

[7]  Jinbao Liu,et al.  Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy , 2020, Theranostics.

[8]  Ping Li,et al.  Asatone and Isoasatone A Against Spodoptera litura Fab. by Acting on Cytochrome P450 Monoxygenases and Glutathione Transferases , 2019, Molecules.

[9]  Y. Niu,et al.  Restoration of FKBP51 protein promotes the progression of castration resistant prostate cancer. , 2019, Annals of translational medicine.

[10]  Lang Li,et al.  Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer , 2019, The Journal of Biological Chemistry.

[11]  M. Gleave,et al.  Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. , 2019, European urology.

[12]  S. Kuang,et al.  Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC) , 2018, The Journal of Biological Chemistry.

[13]  Hongtuan Zhang,et al.  Loss of miR-516a-3p mediates upregulation of ABCC5 in prostate cancer and drives its progression , 2018, OncoTargets and therapy.

[14]  Joshua M. Stuart,et al.  Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer , 2018, Cell.

[15]  Christopher W. Whelan,et al.  Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing , 2018, Cell.

[16]  Zhihua Liu,et al.  Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13 , 2018, Proceedings of the National Academy of Sciences.

[17]  M. Gleave,et al.  Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells , 2018, Proceedings of the National Academy of Sciences.

[18]  E. Niskanen,et al.  Crosstalk between androgen and pro-inflammatory signaling remodels androgen receptor and NF-κB cistrome to reprogram the prostate cancer cell transcriptome , 2016, Nucleic acids research.

[19]  F. Saad,et al.  The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. , 2016, European urology.

[20]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[21]  P. Borst,et al.  ATP-binding Cassette Subfamily C Member 5 (ABCC5) Functions as an Efflux Transporter of Glutamate Conjugates and Analogs* , 2015, The Journal of Biological Chemistry.

[22]  A. Schally,et al.  New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones , 2015, Asian journal of andrology.

[23]  Yezi Zhu,et al.  Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. , 2015, Cancer research.

[24]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[25]  J. Luo,et al.  Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects , 2014, Oncogene.

[26]  Yezi Zhu,et al.  Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer , 2014, Clinical Cancer Research.

[27]  Chawnshang Chang,et al.  Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death. , 2014, Cancer treatment reviews.

[28]  S. Chowdhury,et al.  Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents. , 2014, Cancer treatment reviews.

[29]  J. Bono,et al.  Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. , 2014, European journal of cancer.

[30]  Zhifeng Dong,et al.  ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone , 2012, Breast Cancer Research.

[31]  K. V. Donkena,et al.  Recent advances in understanding hormonal therapy resistant prostate cancer. , 2010, Current cancer drug targets.

[32]  J. Fletcher,et al.  ABC transporters in cancer: more than just drug efflux pumps , 2010, Nature Reviews Cancer.

[33]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[34]  R. Ueda,et al.  The determinants of sensitivity and acquired resistance to gemcitabine differ in non–small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity , 2006, Molecular Cancer Therapeutics.

[35]  C. Shimizu,et al.  Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients , 2006, Breast Cancer Research and Treatment.

[36]  P. Johnston,et al.  The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites , 2005, Molecular Cancer Therapeutics.

[37]  J. Willey,et al.  ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines , 2005, Molecular Cancer.

[38]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.